Nebenwirkungen · Lenvima
LENVIMA 4 mg hard capsules LENVIMA 10 mg hard capsules · Abschnitt 4.8 · PDF-Seite 23
HOS-130623 · Präparat HOS-096939
Across clinical trials in which 1,327 patients received lenvatinib monotherapy in indications other than HCC, Grade ≥ 3 or greater haemorrhage was reported in 2% of patients, 3 patients (0.2%) had a Grade 4 haemorrhage and 8 patients (0.6%) had a Grade 5 reaction including arterial haemorrhage, haemorrhagic stroke, intracranial haemorrhage, intracranial tumour haemorrhage, haematemesis, melaena, haemoptysis and tumour haemorrhage.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-26T15:37:00Z · SHA-256 1c91045dd7ec722373bf25329286d58d4e0b526fe9f67d03a2c83676cb980a84 · Passage 25acdd3ef6b1029264725dfa901f787fc91817ef92bd854a48f5c9afb58b5a99 · Zeichen 31098–31532 im Abschnitt